Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Yao, Ling ^a   Zhang, Yan ^a,b   Chen, Keying ^a   Hu, Xiaofang ^a   Xu, Lisa X ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DOXORUBICIN; INTERLEUKIN 18; SCLEROPROTEIN; ANTINEOPLASTIC ANTIBIOTIC;

ARTICLE; BREAST METASTASIS; BREAST TUMOR; CANCER GROWTH; CANCER RESISTANCE; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; UPREGULATION; VALIDATION PROCESS; DRUG RESISTANCE; FEMALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEOMICS; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-18; PROTEOMICS;

EID: 80052524240     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024684     Document Type: Article

References (74)

1. Gottesman MM, (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
2. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, et al. (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5: 662-668.
3. Hoyt DG, Rusnak JM, Mannix RJ, Modzelewski RA, Johnson CS, et al. (1996) Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res 56: 4146-4149.
4. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, et al. (2001) Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98: 10787-10792.
5. Arlt A, Vorndamm J, Muerkoster S, Yu H, Schmidt WE, et al. (2002) Autocrine production of interleukin 1 beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 62: 910-916.
6. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, et al. (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61: 8851-8858.
7. Wang MY, Chen PS, Prakash E, Hsu HC, Huang HY, et al. (2009) Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res 69: 3482-3491.
8. Strong R, Nakanishi T, Ross D, Fenselau C, (2006) Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells. J Proteome Res 5: 2389-2395.
9. Hu HD, Ye F, Zhang DZ, Hu P, Ren H, et al. (2010) iTRAQ quantitative analysis of multidrug resistance mechanisms in human gastric cancer cells. J Biomed Biotechnol 2010: 571343.
10. Hathout Y, (2007) Approaches to the study of the cell secretome. Expert Rev Proteomics 4: 239-248.
11. Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, et al. (2006) Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5: 157-171.
12. Kulasingam V, Diamandis EP, (2007) Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics 6: 1997-2011.
13. Wu CC, Hsu CW, Chen CD, Yu CJ, Chang KP, et al. (2010) Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics 9: 1100-1117.
14. Wang CL, Wang CI, Liao PC, Chen CD, Liang Y, et al. (2009) Discovery of Retinoblastoma-Associated Binding Protein 46 as a Novel Prognostic Marker for Distant Metastasis in Nonsmall Cell Lung Cancer by Combined Analysis of Cancer Cell Secretome and Pleural Effusion Proteome. Journal of Proteome Research 8: 4428-4440.
15. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, et al. (2005) Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 4: 1487-1502.
16. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B, (2007) Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem 389: 1017-1031.
17. Gewirtz DA, (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741.
18. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, et al. (2001) The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276: 33293-33296.
19. Chen CC, Lau LF, (2009) Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 41: 771-783.
20. Iseri OD, Kars MD, Arpaci F, Gunduz U, (2009) Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemother Pharmacol 65: 447-455.
21. Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, et al. (2008) An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One 3: e1908.
22. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, et al. (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12: 1294-1300.
23. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, et al. (2006) Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699-1712.
24. Gyorffy B, Serra V, Jurchott K, Abdul-Ghani R, Garber M, et al. (2005) Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 24: 7542-7551.
25. Ahn MJ, Lee KH, Ahn JI, Yu DH, Lee HS, et al. (2004) The differential gene expression profiles between sensitive and resistant breast cancer cells to adriamycin by cDNA microarray. Cancer Res Treat 36: 43-49.
26. Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, et al. (2001) Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 20: 1300-1306.
27. Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, et al. (2000) Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 60: 4161-4166.
28. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685.
29. Koike Folgueira MA, Brentani H, Carraro DM, De Camargo Barros Filho M, Hirata Katayama ML, et al. (2009) Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy. Oncol Rep 22: 805-813.
30. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293.
31. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24: 4236-4244.
32. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, et al. (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23: 7265-7277.
33. Dressman HK, Hans C, Bild A, Olson JA, Rosen E, et al. (2006) Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 12: 819-826.
34. Mina L, Soule SE, Badve S, Baehner FL, Baker J, et al. (2007) Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 103: 197-208.
35. Hodgkinson VC, Eagle GL, Drew PJ, Lind MJ, Cawkwell L, (2010) Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Lett 294: 13-24.
36. Gehrmann ML, Hathout Y, Fenselau C, (2004) Evaluation of metabolic labeling for comparative proteomics in breast cancer cells. J Proteome Res 3: 1063-1068.
37. Fu Z, Fenselau C, (2005) Proteomic evidence for roles for nucleolin and poly[ADP-ribosyl] transferase in drug resistance. J Proteome Res 4: 1583-1591.
38. Liu Y, Liu H, Han B, Zhang JT, (2006) Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66: 3248-3255.
39. Chuthapisith S, Layfield R, Kerr ID, Hughes C, Eremin O, (2007) Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 30: 1545-1551.
40. Cortesi L, Barchetti A, De Matteis E, Rossi E, Della Casa L, et al. (2009) Identification of protein clusters predictive of response to chemotherapy in breast cancer patients. J Proteome Res 8: 4916-4933.
41. Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, et al. (2008) Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome. Int J Oncol 33: 549-554.
42. Rivoltini L, Cattoretti G, Arienti F, Mastroianni A, Melani C, et al. (1991) The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. Int J Cancer 47: 746-754.
43. Boivin M, Lane D, Piche A, Rancourt C, (2009) CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol 115: 407-413.
44. Fomarini B, D'Ambrosio C, Natoli C, Tinari N, Silingardi V, et al. (2000) Adhesion to 90 K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood 96: 3282-3285.
45. Lin MT, Chang CC, Chen ST, Chang HL, Su JL, et al. (2004) Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem 279: 24015-24023.
46. Perbal B, Zuntini M, Zambelli D, Serra M, Sciandra M, et al. (2008) Prognostic value of CCN3 in osteosarcoma. Clin Cancer Res 14: 701-709.
47. Furukawa T, Kubota T, Tanino H, Oura S, Yuasa S, et al. (2000) Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res 20: 3657-3658.
48. Smalley KSM, Haass NK, Brafford PA, Lioni M, Flaherty KT, et al. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5: 1136-1144.
49. Haga A, Nagase H, Kito H, Sato T, (1997) Invasive properties of cadmium-resistant human fibrosarcoma HT-1080 cells. Cancer Biochem Biophys 15: 275-284.
50. Liang Y, O'Driscoll L, McDonnell S, Doolan P, Oglesby I, et al. (2004) Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer 111: 484-493.
51. Chen PS, Wang MY, Wu SN, Su JL, Hong CC, et al. (2007) CTGF enhances the motility of breast cancer cells via an integrin-alpha v beta 3-ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci 120: 2053-2065.
52. Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A, et al. (2001) Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 276: 14187-14194.
53. Vallacchi V, Rodolfo M, (2009) Regulatory role of CCN3 in melanoma cell interaction with the extracellular matrix. Cell Adh Migr 3: 7-10.
54. Chen PS, Wang MY, Wu SN, Su JL, Hong CC, et al. (2007) CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci 120: 2053-2065.
55. Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP, et al. (2005) Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res 11: 5809-5820.
56. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, et al. (1994) Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84: 3063-3070.
57. Borsellino N, Belldegrun A, Bonavida B, (1995) Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55: 4633-4639.
58. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, et al. (2010) Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 295: 110-123.
59. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, et al. (2010) Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 16: 3028-3034.
60. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, et al. (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88-91.
61. Dinarello CA, (1999) IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 103: 11-24.
62. Park S, Cheon S, Cho D, (2007) The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol 4: 329-335.
63. Gunel N, Coskun U, Sancak B, Gunel U, Hasdemir O, et al. (2002) Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer 95: 663-667.
64. Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcarcel M, et al. (2006) Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 25: 417-434.
65. Jung MK, Song HK, Kim KE, Hur DY, Kim T, et al. (2006) IL-18 enhances the migration ability of murine melanoma cells through the generation of ROI and the MAPK pathway. Immunol Lett 107: 125-130.
66. Kim KE, Song H, Kim TS, Yoon D, Kim CW, et al. (2007) Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 26: 1468-1476.
67. Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, et al. (2004) IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression. Leuk Res 28: 91-95.
68. Cao Q, Cai W, Niu G, He L, Chen X, (2008) Multimodality imaging of IL-18-binding protein-Fc therapy of experimental lung metastasis. Clin Cancer Res 14: 6137-6145.
69. Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, et al. (1977) Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292-298.
70. Tang XR, Yao L, Chen KY, Hu XF, Xu LX, et al. (2009) Analysis of secretome of breast cancer cell line with an optimized semi-shotgun method. Nucl Sci Tech 20: 286-291.
71. Beissbarth T, Hyde L, Smyth GK, Job C, Boon WM, et al. (2004) Statistical modeling of sequencing errors in SAGE libraries. Bioinformatics 20 (Suppl 1): i31-39.
72. Bendtsen JD, Nielsen H, von Heijne G, Brunak S, (2004) Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 340: 783-795.
73. Nielsen H, Krogh A, (1998) Prediction of signal peptides and signal anchors by a hidden Markov model. Proc Int Conf Intell Syst Mol Biol 6: 122-130.
74. Bendtsen JD, Jensen LJ, Blom N, Von Heijne G, Brunak S, (2004) Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel 17: 349-356.